

Published in final edited form as:

Nat Genet. 2015 July ; 47(7): 717–726. doi:10.1038/ng.3304.

Factors influencing success of clinical genome sequencing across a broad spectrum of disorders

A full list of authors and affiliations appears at the end of the article.

These authors contributed equally to this work.

Abstract

To assess factors influencing the success of whole genome sequencing for mainstream clinical diagnosis, we sequenced 217 individuals from 156 independent cases across a broad spectrum of disorders in whom prior screening had identified no pathogenic variants. We quantified the number of candidate variants identified using different strategies for variant calling, filtering, annotation and prioritisation. We found that jointly calling variants across samples, filtering against both local and external databases, deploying multiple annotation tools and using familial transmission above biological plausibility contributed to accuracy. Overall, we identified disease causing variants in 21% of cases, rising to 34% (23/68) for Mendelian disorders and 57% (8/14) in trios. We also discovered 32 potentially clinically actionable variants in 18 genes unrelated to the referral disorder, though only four were ultimately considered reportable. Our results demonstrate the value of genome sequencing for routine clinical diagnosis, but also highlight many outstanding challenges.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Author for correspondence: mcvean@well.ox.ac.uk.

[†]These authors jointly supervised the work

Author Contributions

P.D. and G.M. jointly supervised and oversaw the WGS500 project. C. Babbs, D. Beeson, P.B., E.B., H. Chapel, R.C., J.F., L.F., D.H., A.H., F.K., U.K., J.C.K., A.H.N., S.Y.P., C.P., F.P., P.R., P.A.R., K.R., A. Schuh, A. Simmons, R.V.T., I.T., H.H.U., P.V., H.W., and A.O.M.W. were Principal Investigators on individual projects. V.J.B., K.B., C.D., O.D., R.D.G., J.K., C.L., M.A.N., N. Petousi, S.E.P., S.R.F.T., T.V., and M.P.W. were Lead Investigators on individual projects. H. Cario, M.F.M., C. Bento, K.D., O.D., R.D.G., D.J., C.L., D.N., E.O., A.B.O., M.P., A. Russo, E. Silverman, P.S.S., E. Sweeney, S.A.W., and M.P.W. contributed clinical samples and clinical data. C.A., M.A., A. Green, S.H., Z.K., S. Lamble, L.L., P.P., G.P-E., A.T., and L.W. prepared libraries and generated whole genome sequences, led by D. Buck (High-Throughput Genomics Group, Oxford) and D. Bentley (Illumina Cambridge Ltd). J. Becq, J. Broxholme, S.F., R.G., E.H., C.H., L.H. P.H., A.K., S. Lise, G.L., D.M., L.M., A. Rimmer, N.S., B.W., C.Y., N. Popitsch performed study-wide bioinformatic analysis of whole genome sequence data, led by J.-B.C. and R.R.C. J.T. performed the whole exome sequence analysis presented in Supplementary Fig. 9. E.E.D., A.V.G., M.H., J.L., H.C.M., S.J.M., K.A.M., A.P., L.Q., and P.A.S. performed project-specific bioinformatic analysis of whole genome sequence data. A.R.A., O.C., A.L.F., A. Gorieli, I.H.G., A.V.G., R.H., J.L., K.A.M., and A.P. performed project-specific genetic and functional validation studies. G.M. wrote the paper with help from H.C.M., J.C.T. and A.O.M.W. and further contributions from S. Lise, D.M., A.P., R.V.T. and S.E.P. J.C. collated information for the paper. P.D. chaired the Steering Committee and the Operations Committee; J.I.B., D. Bentley, G.M., P.R., J.C.T., and A.O.M.W. were members of the Steering Committee; J. Broxholme, D. Buck, J.-B.C., R.C., J.C.K., G.L., G.M., J.C.T., I.T., A.O.M.W., and L.W. were members of the Operations Committee.

Accession Codes

The majority of samples studied in WGS500 were consented for clinical investigation only. A small number of samples were collected for general research and WGS data for these samples are available from the ENA under accession number XXX.

Competing Financial Interests

All authors at Illumina (see affiliations) are employees of Illumina Inc., a public company that develops and markets systems for genetic analysis. GM, GL and PD are founders and shareholders of Genomics Ltd, a company that develops genome analytics.

Introduction

The mainstream application of whole genome sequencing (WGS) in clinical diagnosis holds much promise. In contrast to existing genetic tools, such as targeted gene sequencing, array CGH, and exome sequencing¹⁻⁵, only WGS can characterise all types of genetic variant in all parts of the genome. Such completeness, coupled with efforts to chart the distribution of genetic variation in populations^{6,7}, will enable the identification of pathogenic variants and hence influence diagnosis, genetic counselling and treatment.

Nevertheless, clinical adoption of WGS faces many challenges including cost, speed of delivery, sensitivity, specificity and heterogeneity of variant detection, ambiguities and errors in variant annotation, a substantial informatics burden, and the difficulties of incidental findings^{8,9}. Consequently, while technological improvements to improve speed in critical situations such as neonatal intensive care¹⁰ and detailed evaluations of WGS and whole exome sequencing (WES) in specific disorders¹¹ are opening the opportunity for its wider use, its reach into the clinic is, to date, limited¹². In order for WGS to be adopted as a routine clinical platform, we would need to demonstrate its diagnostic yield for patients with likely genetic disorders identified by clinicians across a broad range of medical specialties, within a hospital setting. Furthermore, the challenges of reliably identifying and validating potential pathogenic variants at scale across such a disease spectrum would need to be met.

In order to address these challenges we undertook the WGS500 programme to sequence 500 patient genomes from diverse genetic disorders referred by a range of medical specialists. For all disorders, study leaders had access to additional samples and /or could follow up with functional studies for validation. Some results from this study have already been published¹³⁻¹⁹. Here, we report an overview of the results from the Mendelian and immunological disorders, representing 156 independent individual cases or families, selected because a strong genetic component was suspected (family history, early-onset, severe disorder) but prior genetic screening had failed to identify any pathogenic variants (Fig. 1). The disorders varied substantially in the number of independent cases recruited, the availability of additional family members and the likely disease model. Here, we identify and quantify the effect on success of factors relating to the genetic architecture of a disease, experimental design and analytical strategy.

Results

Variant calling, filtering and annotation

Individuals were sequenced to an average of 31.8× (range 22.7 – 60.8×) such that on average 82.7% of the genome (88.2% of the exome) was covered to at least 20× (Supplementary Fig. 1). We find no significant correlation between sequencing coverage and diagnostic success (Pearson $r = -0.1$, $P = 0.13$), indicating that, at this depth, fluctuations in coverage in WGS play a minor role in determining success for germline disorders. For the few samples with low levels of contaminating DNA (Supplementary Fig. 1), we took additional care over interpretation of candidate pathogenic variants rather than returning to the patient for additional material; one individual with substantial contamination was excluded.

All samples were processed with the same pipelines for sequencing, variant calling and annotation (Online Methods). Concordance between the WGS data and genotypes from SNP arrays was over 99.9% at heterozygous sites (Supplementary Tables 1 and 2; Supplementary Fig. 2). Our pipeline included two key steps. First, we used a two-stage variant calling procedure with an initial round of independent calling followed by a second round which revisits the evidence in each individual for any variant called across all samples. This approach improves genotype accuracy by, for example, using strong evidence for a variant in a child to enhance support for the same variant in a parent (and vice versa). Joint calling substantially increases the accuracy of *de novo* mutation detection in families. For example, the number of candidate coding *de novo* mutations was reduced from a mean of 32.1 after independent variant calling (filtering against 1000 Genomes and the NHLBI Exome Sequencing Project, ESP) to 2.6 after joint calling of the parents and proband (Supplementary Table 3).

The second key step was that when identifying likely pathogenic variants, in addition to filtering against external data sources, we also filtered against other WGS500 samples. For example, when filtering against external data sources only, individuals had an average of 80.8 rare or novel (frequency < 0.5%) homozygous coding variants, but only 1.5 if, in addition, variants present above this frequency in other WGS500 samples were excluded (Supplementary Table 4). Using control samples sequenced using the same technology and processed through the same pipeline reduced the impact of systematic differences between our studies and others in coverage, sequencing technology, experimental protocol and data processing (Supplementary Fig. 3, Supplementary Table 3).

Finally, we found that the choice of transcript set and annotation software can affect variant annotations²⁰. Comparison of annotation using the RefSeq and Ensembl transcript sets revealed only 44% agreement for putative loss-of-function variants. Similarly, we found agreement of only 66% for loss-of-function annotations and 87% for all exonic annotations between the tools Annovar²¹ and Ensembl's Variant Effect Predictor²². In both comparisons, the greatest discrepancy was for splicing annotations (agreement of 25% between transcript sets and 57% between software tools). Such heterogeneity in how variants are annotated can substantially reduce the efficacy of WGS for clinical analysis. We therefore used multiple annotation approaches to identify candidate variants.

Evaluating biological candidacy of variants

To identify candidate disease-causing variants we used a combination of predicted functional impact, frequency in the population, transmission within a family (where appropriate) and, when multiple independent cases were available, statistical evidence for association (Online Methods). Because most genes harbour large numbers of rare variants^{6,23} many of which are absent from existing databases and affect the protein produced but only a fraction of which may influence disease risk, care has to be taken in interpreting novel variants in known disease genes. To assess the burden of such 'variants of unknown significance' across a range of disorders we defined candidate genes for early-onset epilepsy (EOE), X-linked mental retardation (XLMR) and craniosynostosis (CRS). For EOE we used a semi-automated approach on the basis of a three-tiered system according

to medical genetic and biological information (Online Methods; Supplementary Table 5). Tier 1 comprises the set of known genes for the disorder (from the Human Gene Mutation Database, HGMD²⁴), Tier 2 adds genes known for related disorders (from HGMD) or whose products interact directly with those in Tier 1 (from the Mammalian Protein-Protein Interaction Database, MIPS²⁵), and Tier 3 adds genes in relevant biological pathways (from HGMD and the Gene Ontology database). For XLMR we only examined Tier 1 genes. For CRS we used lists generated by expert curation. For those individuals with the disorder, additional family members were used to identify the most likely pathogenic variants (Supplementary Table 6).

For each disorder, we found multiple unaffected individuals in WGS500 with variants in the candidate genes for XLMR, CRS and EOE that would be interpreted as potentially pathogenic had those individuals presented with the disorder in question. Within the ten known genes for EOE (Tier 1), we found that 3/216 individuals (1.3% of the sample) carried a novel heterozygous candidate variant and one (0.5%) carried a rare homozygous candidate (Fig. 2a); none of these individuals had epilepsy. As the strength of gene candidacy reduced, the effect was increased; 36% of individuals carried at least one heterozygous candidate among the Tier 1 genes or the additional 82 genes implicated in milder forms of epilepsy (Tier 2) and 96% of individuals carried one such variant in a Tier 1 or 2 gene or in one of the 771 genes involved in brain development or function (Tier 3). The proportions for homozygous candidates were 3% and 17% for Tier 1-2 and 1-3 respectively. We found no enrichment for either heterozygous or homozygous candidates in Tier 1-2 genes among the six EOE patients (Supplementary Table 7) and only 2/10 Tier 1-2 variants found in EOE samples are thought to be pathogenic based on family information; for homozygous variants in Tiers 1-3, the figure is 1/3¹⁵ (Supplementary Table 6).

Similar results were found in genes for other disorders. For CRS genes, 57/216 (26%) samples carried at least one novel heterozygous coding variant in the 38 expert-curated known causative genes, though no sample had any rare homozygous coding variants (Supplementary Fig. 4). Five CRS samples carried Tier 1-2 variants, but none are thought to be pathogenic since they were not of *de novo* origin. For X-linked mental retardation (XLMR) genes, the effect is striking: 30/109 male samples (28%) carry at least one previously unreported missense variant at a conserved residue within the 83 known XLMR genes (Fig. 2b). In only two of these (two brothers with MR) was the variant thought to be pathogenic.

We also investigated the burden of potentially pathogenic regulatory variants, focusing on conserved positions in regulatory regions defined by the Ensembl Regulatory Build that are less than 50 kb away from candidate genes (Supplementary Fig. 5). The mean number of novel heterozygous variants per individual was 203 (standard deviation = 102; range 102 - 614), more than twice as many as the equivalent number of novel coding variants (mean = 75, Supplementary Fig. 3), although we note that this number is inflated because there are fewer control individuals in publicly available datasets for regulatory rather than exonic variants. Many individuals had novel or rare variants at conserved sites in regulatory regions close to candidate genes for EOE and CRS (Supplementary Fig. 6). Moreover, in samples from patients with the disorder, there were typically multiple potentially regulatory variants

that were consistent with a plausible inheritance model, although none of these are considered likely pathogenic because stronger candidates were present (Supplementary Table 6).

These results demonstrate that the combined use of gene candidacy, predicted functional consequence, variant frequency and evolutionary conservation, though widely used filters within pipelines for identifying pathogenic candidates, will not, by themselves, differentiate between pathogenic and non-pathogenic variants. Naïve application of such rules will lead to a high rate of false positive diagnosis, even in rare disorders within limited numbers of known genes. Moreover, focusing only on candidate genes will lead to a high false negative rate; of the eight EOE, CRS or XLMR families for which a strong candidate (Class A-C) for the pathogenic variant has been identified (Supplementary Table 6), only four of these variants are in candidate genes found using automated database searches (Tier 1, 2 or 3). In this study, as in others, additional evidence, such as functional data, familial transmission, *de novo* status and screens of other patients, was needed to establish pathogenicity.

Overview of findings

In 33 of the 156 cases (21%), we identified at least one variant with a high level of evidence of pathogenicity (Class A, B or C as described in Online Methods; Figure 1; Table 1; Supplementary Table 8). These comprised five nonsense variants, fifteen missense, three noncoding, two frameshifts, one in-frame indel, five variants that disrupt splicing, and two compound heterozygotes, each with one missense and one either nonsense or splicing variant (and additionally one variant that was reported independently of WGS500). Together, we identified twelve cases with variants in novel genes for which we found additional compelling genetic and/or functional evidence of pathogenicity (Class A), four cases with variants in genes known for other phenotypes but not for the disorder in question, supported by additional genetic and/or functional evidence (Class B), and seventeen cases with variants in genes already known for that phenotype (Class C). This rate of success is comparable to recent exome sequencing studies in various disorders^{3,5,8,26}. Below we describe the range of the findings and some of the outstanding challenges identified.

Variants missed by prior genetic testing

We identified four cases where a candidate variant lay within a gene that had previously been screened by a clinical or research genetic laboratory (UK or overseas) but had been missed. These were variants in *UMOD* in familial juvenile hyperuricemic nephropathy (FJHN), in *KCNQ1* in long QT syndrome and in *APC* and *MSH6* in multiple adenoma. The rate of false negative results from Sanger sequencing is likely to vary considerably between genes and types of variant. Nevertheless, across the samples studied here, a relatively small fraction (2.5%) of cases resulted from false negative tests in standard clinical genetics testing.

Challenges in establishing pathogenicity

For several disorders, likely pathogenic variants were identified in genes not reported previously for those conditions or related phenotypes. When additional variants of major coding consequence were found in screens of other cases (and not controls), the evidence for

pathogenicity was considered strong, including for *POLE* and *POLD1* in multiple adenomas/colorectal cancer¹⁹, *TCF12* in Saethre-Chotzen-like syndrome¹⁶, *ALG2* for congenital myasthenic syndrome¹⁷, and *C15ORF41* in congenital dyserythropoetic anaemia, type 1¹⁴. In some cases, mouse models provided supportive evidence (e.g. confirming the role of *SPTBN2* in cerebellar ataxia¹⁸), and/or functional work demonstrated that the variant affects protein function (e.g. a *KCNT1* *de novo* mutation found in an Ohtahara syndrome patient was shown to affect potassium channel activity¹⁵).

In six cases, likely pathogenic variants were identified in genes where variants cause disorders with related phenotypes. For example, a *de novo* mutation that disrupts *CBL* splicing (NM_005188:exon9:c.1228-1G>A) was identified in a patient with severe epilepsy, microcephaly, and developmental delay¹⁵. Cbl is a ubiquitin ligase that regulates the Ras/MAPK pathway²⁷, and heterozygous missense variants in *CBL* cause facial, cutaneous and cardiac abnormalities, hypotonia and developmental delay^{28,29}, as well as microcephaly and a predisposition to juvenile myelomonocytic leukemia^{30,31}. However, whilst our patient had unusual cutaneous and cardiac features, these were not typical of NCFC syndrome, and review by clinicians did not alter the original diagnosis. *CBL* variants have previously been noted for their variable phenotypes and incomplete penetrance³¹. Thus, the *CBL* variant is a strong candidate, but no other likely pathogenic variants in *CBL* were identified in a panel of over 500 other epilepsy patients¹⁵.

The difficulties in establishing pathogenicity are also illustrated by a *de novo* missense mutation (NM_031407:c.329G>A:p.R110Q) in *HUWE1* identified in a girl with craniosynostosis and learning difficulties (Fig. 3a; Supplementary Note). Mutations in *HUWE1* are reported to cause X-linked mental retardation and macrocephaly³²⁻³⁴, though not previously CRS. The mutation affects a highly conserved residue in a domain of unknown function (DUF908; Supplementary Fig. 7). The gene spans 154,641 bp and comprises 84 exons, and, because of extensive heterogeneity in CRS, the contribution to the disease is likely to be low. Thus, it was not surprising that no other *HUWE1* mutations were found in a cohort of 47 unrelated cases with complex CRS. The mutation originated on the paternal X chromosome (Fig. 3b; Supplementary Fig. 7). Unexpectedly, cells from the patient show preferential inactivation of the maternally inherited, wild-type X (Fig. 3c) and, consistent with these two observations, only the mutant allele was expressed in the tissues available (fibroblast and transformed lymphoblasts) (Fig. 3d). Seven other X-linked *de novo* point mutations (three in genes: a 5'UTR change in *CCDC160* and intronic changes in *FRMPD4* and *IGSF1*) were identified in the same individual (Fig. 3e), though none were considered pathogenic. The finding of a substitution at a highly conserved residue in a known XLMR gene, combined with exclusive expression of the mutant allele, suggested that this mutation contributed at least to the learning difficulties in this child, but that this is a highly unusual case, and hence it was challenging to establish true pathogenicity. Recently, however, we identified, using WES, a different *de novo* hemizygous mutation altering the same amino acid of *HUWE1* (c.328C>T encoding p.R110W) in a boy presenting with metopic craniosynostosis, moderate-severe learning disability and other dysmorphic features, supporting the evidence for causality.

Candidates for pathogenic regulatory variants

Strong candidate pathogenic variants were detected outside the coding fraction of the genome in two conditions. The same variant at a highly conserved base (chr7:100318468 G>A; Fig. 4a) within the 5' UTR of the erythropoietin gene *EPO* was identified in two independent families with erythrocytosis and co-segregated with the disease (Fig. 4b; Supplementary Note). Moreover, this is the only rare exonic variant found in an 8 Mb region that is identical-by-descent in the affected individuals in these two unrelated families (the only such region), suggesting that it had a single, and probably recent, mutational origin. *EPO* is a strong candidate gene as erythropoietin is essential for red cell production and increased levels cause increased red cell mass, the hallmark of erythrocytosis^{35,36}. However, genetic variation in *EPO* has not been linked previously with erythrocytosis and further functional data would be necessary to prove causality definitively.

In another case, a complex event leading to deletion of 1.4 kb of the X chromosome and insertion of 50 kb from chromosome 2p (Fig. 4c; Supplementary Fig. 8) was discovered in a patient with X-linked hypoparathyroidism (Supplementary Note). This variant lies 81.5 kb downstream of *SOX3*, segregates with the disease (Fig. 4d) and is similar to an event reported previously in an independent kindred³⁷. *SOX3* is a strong candidate as it influences the development of the parathyroid gland³⁸. Although the pathogenicity for these variants is not proven, that such candidates can be identified using WGS demonstrates the value of screening the noncoding genome.

Incidental findings

The identification of variants unrelated to the referred condition, but which have potential clinical and actionable significance, is a major challenge for WGS. To evaluate the burden of such incidental findings, we followed the American College of Medical Genetics and Genomics' recommendations³⁹ and used HGMD²⁴ assignments of pathogenic status to identify 32 variants in 18 genes of possible clinical significance (four nonsense, three splice-site and 25 nonsynonymous variants). After detailed and lengthy review of the literature and curated variant databases, 26 could be eliminated (Supplementary Table 9), leaving six variants in four genes, each present in a single case (Table 2). Although the majority of these variants have been published in association with a relevant disease, major doubts remain about their clinical interpretation due to incomplete information on (1) variant frequencies in large populations of healthy people, (2) phenotypes when segregating within families and (3) corroborative functional studies⁴⁰. Where the variant occurs at significant frequency in public databases (e.g. the *RYR1* variants), the rarity of associated case reports suggests that penetrance is low or indeed zero. Even in the most apparently clear-cut case of a nonsense variant in *BRCA2*, the actual disease risk is likely to be reduced in the absence of a documented family history⁴¹.

Any decision on clinical action must balance multiple potential harms (invasion of personal autonomy, the severity of proposed preventive intervention, associated healthcare costs) against the anticipated benefits to health. We propose that only four variants are clinically reportable (Table 2), whilst a further two variants are of uncertain significance and warrant further investigation (Table 2). For example, the R397W variant in *KCNQ1* is potentially

associated with long QT syndrome (LQTS) and sudden death. The frequency of this single variant in EVS exceeds that of LQTS overall, suggesting very low absolute risk; nevertheless it is probably reasonable to recommend avoidance of certain classes of medication (even if the subject does not have any obvious ECG abnormality) as this intervention can, very occasionally, be lifesaving. By contrast, we do not believe that intensive electrophysiological investigation or clinical cascade screening of the extended family are indicated. These observations highlight the urgent need for unbiased data from large biobanks to support clinical decision making.

Discussion

The goal of the WGS500 study was to evaluate the potential value of WGS in mainstream genetic diagnosis. In routine clinical settings the opportunities for time-consuming investigation of multiple variants emerging from WGS are limited. We identified multiple strategies in analysis (joint variant calling, filtering of variants against local databases and the use of multiple annotation algorithms) that improve the reliability of variants called and improved sensitivity and specificity in detecting candidate disease-causing variants.

With these innovations, WGS proved to be effective for molecular diagnosis of severe disorders for which a strong genetic component was suspected, but where screening of known genes had failed previously to identify candidates. Overall, WGS identified a pathogenic variant in 33/156 cases (21%), 23/68 (33.8%) Mendelian cases (class A, B or C in category 1 or 2), increasing to 57% (8/14) in cases where *de novo* or recessive models were suspected and both parents sequenced (category 2.1) (Supplementary Table 8). The majority of these variants lie within genes, hence are typically accessible through WES. However, in an independent study of 141 exomes, 3/33 sites reported in Table 1 lay outside the exome target and a further six lay within the target, but had low coverage (median < 20×; Supplementary Fig. 9). If a minimum of six reads, three of which support the variant, are required for detecting a novel heterozygous variant, we estimate that 15% of causal variants identified in this WGS study (including coding and non-coding changes) would likely have been missed by WES (0.5% in WGS500). Conversely, using 20 variant sites identified as causal from an independent exome sequencing project, we estimate that WGS at this coverage has 99.6% power to identify a novel heterozygous variant (compared with 96.1% in WES; Supplementary Fig. 9).

Moreover, WGS has additional benefits. For example, in the CRS case discussed above, WGS was important for a) identifying the *HUWE1* mutation, b) identifying nearby variants for establishing parent of origin, so we could subsequently show that only the mutant chromosome was being expressed, and c) for assessing other *de novo* mutations on the X that might affect X chromosome inactivation. The latter two points could not have been addressed with WES data. Moreover, WGS identified, in other cases, two likely pathogenic non-coding variants and unusual chromosomal features including large deletions (for example, a 30 Mb deletion on the X chromosome of a patient with congenital myasthenia, though this is not thought to be relevant to the disorder), distant consanguinity (Supplementary Fig. 10) and uniparental disomy (as in the case of a child with Ohtahara Syndrome¹⁵).

In other types of disorder, WGS proved less successful. The number of candidate variants in families with dominantly inherited disorders makes functional validation time-consuming, and many such cases remain in active follow up. Furthermore, our hypothesis that extreme forms of complex disorders (young onset, severe disease) would enrich for monogenic forms was not confirmed. In only two cases out of 49 (one case of common variable immunodeficiency disorder and one in inflammatory bowel disease) did WGS on unrelated individuals with extreme immune-related disorders identify strong candidates for pathogenic variants, despite substantial sample sizes ($n = 34$ for CVID, $n = 15$ for IBD). Several other candidates have been identified, but pathogenicity has not been confirmed. This low success rate likely reflects the influence of multiple genetic factors, even in extreme cases. Only very large patient cohorts are well-powered for identifying novel genes with a modest contribution to the phenotype^{42,43} and, in any specific case, it will be difficult to assign pathogenicity to any particular variant.

Our results also highlight the outstanding challenges of WGS interpretation. Every individual carries multiple rare variants that could potentially be assessed as pathogenic for a given disorder on the basis of biological information about the gene, the coding consequence of the variant and its frequency within the population. Such variants may be benign, or have variable penetrance, making their clinical interpretation without additional information (such as *de novo* status or co-segregation with the disease within a family) challenging. Conversely, rigid application of biological candidacy filters will lead to false negatives. Ultimately, WGS will only be able to reliably assess the diagnostic and predictive value of any specific variant if it, or another variant in the same gene, is identified in other individuals with the same disorder for whom detailed phenotypic and clinical data are available.

Finally, the identification of pathogenic variants, exclusion of potential candidate variants and identification of incidental findings relied on close collaboration between analysts, the scientists knowledgeable about the disease and genes and clinicians expert in the specific disorders. The availability of resources and expertise for functional validation studies were critical to the assignment of causality. Provision of this network may be challenging to establish in a clinical setting but it will be an important aspect of successful translation of WGS.

Online Methods

Overview of the WGS500 Project Consortium

WGS was carried out as part of a collaboration between the Wellcome Trust Centre for Human Genetics at the University of Oxford, the Oxford NIHR Biomedical Research Centre and Illumina Inc. We sought to sequence 500 whole genomes from patients in whom findings could have immediate clinical utility in terms of diagnosis, prognosis, treatment selection, or genetic counselling and reproductive choices.

Process and criteria for sample inclusion

Proposals were invited from clinicians and researchers in Oxford, commencing in December 2010, and were reviewed by a scientific Steering Committee. Known candidate genes and large chromosomal copy number changes had to have been excluded for the patient to be included in the study, to maximise the likelihood of identifying variants in novel disease genes.

Projects were categorised as follows:

1. Families with suspected Mendelian conditions with affected individuals across multiple generations (dominant or recessive). In these cases, we usually sequenced one or a few family members (chosen to maximise power for exclusion analysis) and obtained SNP array data on all available others, in order to identify regions identical by descent between affected individuals. These cases were further subdivided into:
 - 1.1.1. Dominant model suspected
 - 1.1.2. Recessive model suspected (often due to consanguinity)
 - 1.1.3. X-linked model suspected
 - 1.1.4. Multiple unrelated families with linkage to the same region/s
2. Families with suspected Mendelian conditions with one or more affected individuals in a single generation. For these, we hypothesised that they were due to *de novo* or recessive mutations. We used these sub-classifications:
 - 2.1. Affected offspring and both parents sequenced.
 - 2.2. Only affected offspring sequenced, not parents.
3. Cohort of unrelated sporadic patients with no known family history.
4. Individuals with extreme forms of common disorders (e.g. early onset or severe forms).

Ethics

Individual researchers had explicit research consent to undertake genetic investigation into the cause of the relevant disease, and/or samples were obtained with clinical consent as part of efforts to identify the cause of the patient's disease. Ethics committee reference numbers for every individual research project have been provided to the journal editors.

Sequencing library Preparation

3–5 µg of DNA was obtained from each individual, usually from blood, or otherwise from saliva or immortalised cell lines. Samples were diluted to 80 ng/µl in 10 mM Tris-Cl, pH 8.5, then quantified using the High Sensitivity Qubit system (Invitrogen). Sample integrity was assessed using 1% E-Gel EX (Invitrogen). Focused ultrasonication was carried out to fragment 2 µg of DNA using the Covaris S2 system with the following settings: duty cycle = 10%, intensity = 5%, cycles/burst = 200 and time = 60 s. Libraries were constructed using

the NEBNext DNA Sample Prep Master Mix Set 1 Kit (New England Biolabs), with minor modifications. Ligation of adapters was performed using 6 µl of Illumina Adapters (Multiplexing Sample Preparation Oligonucleotide Kit). Ligated libraries were size-selected using 2% E-Gel EX (Invitrogen) and the distribution of fragments in the purified fraction was determined using Tapestation 1DK system (Agilent/Lab901). Each library was PCR-enriched with 25 µM each of the following custom primers:

Multiplex PCR primer 1.0:

5'-

AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCT-3'

Index primer:

5'-

CAAGCAGAAGACGGCATACGAGAT[INDEX]CAGTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCT-3'

Indexes were 8 bp long and formed part of an indexing system developed in-house⁵⁹. Four independent PCRs were prepared per sample using 25% volume of the pre-PCR library each. After 8 cycles of PCR (cycling conditions as per Illumina recommendations) the four reactions were pooled and purified with AMPure XP beads (Beckman Coulter, Inc.). The final size distribution was determined using a Tapestation 1DK system (Agilent/Lab901). The concentration of each library was determined by Real-time PCR using the Agilent qPCR Library Quantification Kit and an MX3005P instrument (Agilent).

Whole genome sequencing and quality control

WGS was performed on either the Illumina HiSeq2000 or the HighSeq2500 run in standard mode, either by the Oxford Genomics Centre at the Wellcome Trust Centre for Human Genetics, or by Illumina Cambridge Ltd.. We generated 100 bp reads and used v2.5 or v3 clustering and sequencing chemistry. A PhiX control was spiked into the libraries. We aimed for a mean coverage of 30× and obtained a minimum of 22.7×. The mode number of lanes required to reach the desired coverage was $2\frac{1}{3}$.

We used the recommended quality metrics in the Illumina Sequence Analysis Viewer in analysing each lane. Additionally, we generated our own quality metrics for each lane (or, in the case of multiplexes, each part of a lane), and required the following criteria to be met: <2% duplicate pairs; most frequent kmer <2%; >99% mapped; <2.5% read pairs mapping to different chromosomes; mean insert size between 340 bp and 440 bp, with a median absolute deviation of <30bp; approximately uniform genomic coverage by GC content; ~1% exonic coverage; <2% N bases at any cycle; approximately equal number of reads per tag (three samples multiplexed per lane), standard deviation <25%.

Read mapping

Sequence reads were generated using the Illumina offline basecaller (OLB; v1.9.3) and mapped to the GRCh37d5 human reference sequence. This reference genome was obtained from the 1000 Genomes Project and is based on hg19 but contains a 35.48 Mb decoy chromosome that reduces misalignment of repetitive sequence and improves accuracy of SNP discovery. Mapping was performed using BWA (v0.5.6)⁶⁰ and Stampy (versions 1.0.12 - 1.0.22; see URLs)⁶¹, and merging and deduplication using Picard (v1.67; see URLs).

SNP and indel calling and genotyping

Variant calling was performed with Platypus⁶² (version 0.1.9; see URLs) using the default settings. This algorithm can detect SNPs and short indels (<50 bp), and is sensitive to somatic mosaic mutations at low allele frequencies^{63,64}.

The variant calling included two stages. First, we used Platypus to identify SNPs and short indels in all samples individually (raw calling). We then ran it a second time to genotype the union of all variants in all samples. We did the raw calling on groups of related samples together (“joint calling”), so that the same sites were interrogated for all samples in the family (i.e. it was possible to distinguish homozygous reference from a missing call), and so that the observation of a variant in one of the individuals in the family reduced the required threshold for calling it in the others (see Rimmer, et al. ⁶²).

We retained variants with a PASS flag that had a posterior probability (phred scale) of >20 that the variant segregates. Variants with a “clustered” flag (within 25 bp of another variant) were manually checked in IGV⁶⁵ but not discounted.

To check for sample contamination, we plotted the distribution of the ratio of the number of reads containing the alternate allele to the total number of reads (ALT:TOTAL) for known SNPs (from dbSNP) and novel SNPs for each sample (Supplementary Figure 1D). To check for duplicates and cryptically related individuals, we ran principal components analysis on the WGS500 data. We included the three ethnic groups (CEU, YRI and JPT/CHB) from the HapMap project, which allowed us to identify a few individuals with a particularly high number of variants as ancestry outliers.

Filtering variants in trios

There were fifteen families in WGS500 from which both the parents and one or more affected children were sequenced: six trios and one quartet with early-onset epilepsy (EOE), a trio with hypertrophic cardiomyopathy (HCM), a trio with erythrocytosis (ERY) (with mother and daughter affected), four trios with craniosynostosis (CRS), a trio with Saethre-Chotzen syndrome (SC; a type of CRS), and a quartet with X-linked mental retardation (XLMR). If the parents were unaffected and only one child was affected, the initial hypothesis was that the causal mutation was *de novo*. To screen for these variants, we searched for variants that were absent from all public databases (1000 Genomes, dbSNP, ESP) and from other WGS500 samples, and that had been confidently called as heterozygous in the child and as homozygous reference in the parents (genotype log likelihood ratio, GLLR < -5). (This latter criterion on the GLLR was not always applied

when analyzing data for specific projects.) Supplementary Table 3 demonstrates the value of applying these different filters.

We also investigated a simple recessive model in these families. Homozygous variants in the affected child (or children) had to have a frequency less than 0.5% in 1000 Genomes and ESP (corresponding to an expected homozygous frequency of 1 in 40,000), and there had to be 0 homozygotes and ≤ 2 heterozygotes amongst the unrelated WGS500 samples. We required the parents to be called as heterozygous. Results of these filters are shown in Supplementary Table 4. When filtering for compound recessive candidates (in which the child had two rare heterozygous coding variants in the same gene, one inherited from each parent) and X-linked recessive candidates, we used the same frequency thresholds as for the simple recessive case.

Annotation of variants

The functional consequences of variants were predicted using several programmes. We used ANNOVAR (February 2013 version)⁶⁶ to annotate variants with respect to RefSeq genes, adding information about segmental duplications, conservation (based on the UCSC alignment of 46 mammalian genomes), GERP, SIFT, MutationTaster, phyloP and PolyPhen2 scores, dbSNP identifiers (version 1.35), and frequency in the NHLBI Exome Sequencing Project (see URLs) and Phase 1 of the 1000 Genomes Project⁶. We also annotated all variants using the Variant Effect Predictor from Ensembl (version 69) and the nonsynonymous SNPs using PolyPhen2 (version 2.2.2r405).

Detection of copy number variants and extended homozygosity

We used several different methods to search for copy number variants (CNVs). 1) We generated count profiles for each individual by dividing each chromosome into 10 kb bins and counting number of reads in each bin. For each chromosome, we applied principal components analysis to the log of the counts (training set - one per family), and then plotted the residuals of the predicted PCs along the chromosome. This procedure served to remove noise in the data due to biases in sequence composition. Candidate CNVs (down to about 10 kb) were identified as outliers visually. 2) We applied OncoSNP-SEQ⁶⁷ in germline mode to a subset of 300,000 reliable SNPs across the genome. Coverage and read counts at these locations were used as proxy for the intensity and B-allelic-frequency under a specific model of the Hidden Markov Model intended for next-generation sequencing data. 3) To identify exon-level CNVs, we used ExomeDepth⁶⁸.

To search for long regions of homozygosity (LROHs), we calculated the fraction of heterozygous SNPs in 10 kb bins along the chromosomes for each individual, averaged these over 1 Mb regions, and plotted them, ignoring centromeric and other repetitive regions. We classed as “homozygous” any segments with a heterozygous/homozygous ratio < 0.2 ; this empirically chosen threshold avoided large homozygous regions being interrupted by genotyping errors in difficult regions, but clearly distinguished them from the rest of the genome. Homozygous regions up to 4 Mb size are common in demonstrably outbred individuals⁶⁹. Consanguinity had already been reported for many of the thirty-nine individuals who had LROHs larger than 4 Mb (Supplementary Figure 10), but in cases for

whom it had not, this finding prompted analysts to search for rare homozygous variants within these regions.

SNP array data

Illumina SNP arrays were run on some WGS500 samples and other relatives. This was to check the genotyping accuracy of our sequencing pipeline, to refine linkage regions, to confirm familial relationships, and, in two cases, to investigate whether large stretches of homozygosity were likely due to uniparental disomy or unreported consanguinity. We ran 200 ng of DNA on the Illumina Human CytoSNP12 array or on the 1M array (Illumina Inc.), following the manufacturer's guidelines. Concordance between the CytoSNP12 genotypes and the WGS data is shown in Supplementary Tables 1 and 2, and the dependence on coverage in Supplementary Figure 2. In most cases, array-CGH had already been performed prior to submission of samples, but we also used QuantiSNP⁷⁰ to check for CNVs, as well as Nexus Copy Number version 7 (BioDiscovery, Hawthorn, CA). We used MERLIN⁷¹ in familial studies to identify regions identical-by-descent.

Assessment of coverage in WGS500 and exome sequence data

After removing duplicate reads, we used bedtools⁷² to measure coverage in all WGS500 samples, and examined the cumulative distributions across the genome and exome (CCDS transcripts) (Supplementary Figure 1A,B). In order to compare this with a typical exome sequencing experiment, we took 141 whole exome datasets that had been captured using the Roche Nimblegen SeqCap EZ v.2.0 kit at the Oxford Biomedical Research Centre, removed duplicate reads, and measured coverage at each position in the CCDS transcripts. We compared the exome-wide coverage distributions between WGS500 and these exomes (Supplementary Figure 1), as well as the coverage at specific variants thought to be causal (Supplementary Figure 9).

Identifying variants of clinical relevance

Following variant calling and annotation, cases from specific projects were investigated by different analysts, and variants prioritised on the basis of mode of inheritance, functional consequence, population frequency, evolutionary consequence of position and biological relevance. Where available, parental data, linkage information and repeated occurrence across multiple independent cases with a disorder were used to aid prioritisation. Validation of biological consequence and/or screening of additional cohorts was used to confirm pathogenicity. Where a previously described variant or variant class (e.g. loss of function, frameshift) was observed in a known gene for a disorder, it was assumed to be pathogenic and missed by prior screening. All putatively causative variants were confirmed using Sanger sequencing. Information was returned to clinicians responsible for managing individual patients, who decided whether and how information was reported to them.

Classification system for results

We categorised the results for each independent case into five classes, as follows:

- Class A: Mutation found in a novel gene, with additional genetic evidence (in unrelated cases) and/or functional data supporting causality.

- Class B: Mutation found in a gene known for a different phenotype, with additional genetic evidence and/or functional data supporting causality.
- Class C: Mutation found in a known gene for this phenotype.
- Class D: Mutation found in a novel gene, with further genetic and functional validation studies in progress.
- Class E: No single candidate yet, or negative results for validation of original candidates.

The results for all projects are summarised in Figure 1. Note that one of the CVID cases recovered antibody production, and was thus found to have been misdiagnosed.

Analysis of gene/variant tiering strategy

For eight of the thirteen families mentioned above from which we sequenced the affected child/children and healthy parents, we have identified the causal mutation with a reasonable level of confidence (class A, B or C in Supplementary Table 6). Thus, we used these families as test cases for the analysis in this section.

We compiled tiered lists of candidate genes for each of the three diseases: EOE, CRS and XLMR. For EOE (Supplementary Table 5), Tier 1 contains genes that are recorded in the Human Gene Mutation Database (HGMD)²⁴ as causing Ohtahara syndrome or epileptic encephalopathy, Tier 2 contains genes that interact with Tier 1 genes (according to the Mammalian Protein-Protein Interaction Database (MIPS) database²⁵) or that are listed in HGMD as causing more general epilepsy, and Tier 3 contains genes that are involved in biological pathways known to be involved in pathogenesis. For CRS, Tier 1 is a hand-curated list of genes mentioned in the literature as causing CRS in two or more cases, Tier 2 is a list of additional genes associated with the term “craniosynostosis” in the the Copenhagen disease gene association list (see URLs), and Tier 3 comprises additional orthologs of 270 mouse genes that are expressed in the skull⁷³ (Eurexpress database; see URLs). For XLMR, we compiled the Tier 1 list by searching HGMD for “mental retardation” and “intellectual disability” and then restricting to chrX; we did not consider additional tiers since Tier 1 already contained 83 genes.

We analysed the mutational burden in these genes for all 216 samples, having excluded the contaminated sample HCM_2361 (Supplementary Figure 1. Specifically, we screened for coding variants in these genes that would appear to fit a *de novo* dominant (DN), simple recessive (SR) or X-linked (XL) model in the absence of parental information, according to the following criteria:

- *De novo* model: novel variant heterozygous in proband and absent from 1000 Genomes, ESP and other unrelated WGS500 samples
- Simple recessive model: novel or very rare variant homozygous in proband, frequency <0.5% in 1000 Genomes and ESP, with no other homozygotes and ≤ 2 heterozygotes amongst the unrelated WGS500 samples

- X-linked recessive model: novel or very rare variant hemizygous in male proband, frequency <0.5% in 1000 Genomes and ESP, and no other homozygous females or hemizygous males and ≤ 2 heterozygotes amongst the unrelated WGS500 samples

A variant was considered “coding” if it was annotated by ANNOVAR⁶⁶ as missense, stop gain or stop loss, an indel, or within a splice site, for one or more transcripts, and “conserved” if it had a GERP or phyloP score greater than 2, or was in a constrained element as defined by the UCSC 46-way alignment. We also used VEP to add information about regulatory regions from the Ensembl V65 Regulatory Build (see URLs).

Actionable, pathogenic incidental findings

We followed the guidelines of the American College of Medical Genetics and Genomics³⁹ for reporting incidental findings. To identify potentially disease-causing mutations, we first took all the mutations in HGMD²⁴, left-aligned the indels, and removed variants with erroneous reference alleles. We retained those classed as “DM” (disease mutation) that were within 10 bp of an exon of a gene in Table 1 of Green *et al.*³⁹. We then searched all WGS500 samples for these mutations, and for nonsense or frameshift mutations in the same genes, which would be expected to be pathogenic. We removed any variants with a frequency >1% in 1000 Genomes or the Exome Variant Server. Variants that were i) classified as variants of unknown significance in curated, disease-specific mutation databases ii) had high frequency in Exome Variant Server iii) had negative functional data iv) showed lack of segregation in literature reports or v) were unlikely to be of significance from their sequence context (e.g. splicing variants without clear splicing signatures) were removed. These are listed in Supplementary Table 9. The remaining variants (Table 2) were then scrutinized by a panel of clinical experts, who decided which variants had enough data supporting pathogenicity to report.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Jenny C Taylor^{#1,2}, Hilary C Martin^{#2}, Stefano Lise², John Broxholme², Jean-Baptiste Cazier², Andy Rimmer², Alexander Kanapin², Gerton Lunter², Simon Fiddy², Chris Allan², A. Radu Aricescu², Moustafa Attar², Christian Babbs³, Jennifer Becq⁴, David Beeson⁵, Celeste Bento⁶, Patricia Bignell⁷, Edward Blair⁸, Veronica J Buckle³, Katherine Bull^{2,9}, Ondrej Cais¹⁰, Holger Cario¹¹, Helen Chapel¹², Richard R Copley^{1,2}, Richard Cornall⁹, Jude Craft^{1,2}, Karin Dahan^{13,14}, Emma E Davenport², Calliope Dendrou¹⁵, Olivier Devuyst¹⁶, Aimée L Fenwick¹⁷, Jonathan Flint², Lars Fugger¹⁵, Rodney D Gilbert¹⁸, Anne Goriely¹⁷, Angie Green², Ingo H. Greger¹⁰, Russell Grocock⁴, Anja V Gruszczyk¹⁷, Robert Hastings¹⁹, Edouard Hatton², Doug Higgs³, Adrian Hill^{2,20}, Chris Holmes^{2,21}, Malcolm Howard^{1,2}, Linda Hughes², Peter Humburg², David Johnson²², Fredrik Karpe²³, Zoya Kingsbury⁴, Usha Kini⁸, Julian C Knight², Jonathan Krohn², Sarah Lamble², Craig Langman²⁴, Lorne Lonie², Joshua Luck¹⁷, Davis McCarthy², Simon J McGowan¹⁷, Mary

Frances McMullin²⁵, Kerry A Miller¹⁷, Lisa Murray⁴, Andrea H Németh²⁶, M Andrew Nesbit²⁷, David Nutt²⁸, Elizabeth Ormondroyd¹⁹, Annette Bang Oturai²⁹, Alistair Pagnamenta^{1,2}, Smita Y Patel¹², Melanie Percy³⁰, Nayia Petousi³¹, Paolo Piazza², Sian E Piret²⁷, Guadalupe Polanco-Echeverry², Niko Popitsch^{1,2}, Fiona Powrie³², Chris Pugh³¹, Lynn Quek³, Peter A Robbins³³, Kathryn Robson³, Alexandra Russo³⁴, Natasha Sahgal², Pauline A van Schouwenburg¹², Anna Schuh^{1,35}, Earl Silverman³⁶, Alison Simmons^{15,32}, Per Soelberg Sørensen³⁷, Elizabeth Sweeney³⁸, John Taylor^{1,39}, Rajesh V Thakker²⁷, Ian Tomlinson^{1,2}, Amy Trebes², Stephen RF Twigg¹⁷, Holm H Uhlig³², Paresh Vyas³, Tim Vyse⁴⁰, Steven A Wall⁴¹, Hugh Watkins¹⁹, Michael P Whyte⁴², Lorna Witty², Ben Wright², Chris Yau², David Buck², Sean Humphray⁴, Peter J Ratcliffe³¹, John I Bell⁴³, Andrew OM Wilkie¹⁷, David Bentley⁴, Peter Donnelly^{2,21,†}, and Gilean McVean^{2,†}

Affiliations

¹NIHR Comprehensive Biomedical Research Centre, Oxford, UK ²Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK ³MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK ⁴Illumina Cambridge Limited, Saffron Walden, UK ⁵Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK ⁶Hematology Department, Centro Hospitalar e Universitário de Coimbra, Portugal ⁷Molecular Haematology Department, Oxford University Hospitals NHS Trust, Oxford, UK ⁸Department of Clinical Genetics, Oxford University Hospitals NHS Trust, Oxford, UK ⁹Centre for Cellular and Molecular Physiology, University of Oxford, Oxford, UK ¹⁰Neurobiology Division, MRC Laboratory of Molecular Biology, Cambridge, UK ¹¹Department of Pediatrics and Adolescent Medicine, University Medical Center, Ulm, Germany ¹²Primary Immunodeficiency Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK ¹³Centre de Génétique Humaine, Institut de Génétique et de Pathologie, Gosselies, Belgium ¹⁴Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium ¹⁵MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK ¹⁶Institute of Physiology, Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland ¹⁷Clinical Genetics Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK ¹⁸University Hospital Southampton NHS Foundation Trust, University of Southampton, Southampton, UK ¹⁹Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK ²⁰The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK ²¹Department of Statistics, University of Oxford, Oxford, UK ²²Craniofacial Unit, Department of Plastic and Reconstructive Surgery, Oxford University Hospitals NHS Trust, Oxford, UK ²³Oxford Laboratory for Integrative Physiology, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK ²⁴Kidney Diseases, Feinberg School of Medicine, Northwestern University and the Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, USA ²⁵Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK ²⁶Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

²⁷Academic Endocrine Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK ²⁸Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College, London, UK ²⁹Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark ³⁰Department of Haematology, Belfast City Hospital, Belfast, UK ³¹Nuffield Department of Medicine, University of Oxford, Oxford, UK ³²Translational Gastroenterology Unit, University of Oxford, Oxford, UK ³³Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK ³⁴Department of Pediatrics, University Hospital, Mainz, Germany ³⁵Department of Oncology, University of Oxford, Oxford, UK ³⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada ³⁷Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark ³⁸Department of Clinical Genetics, Liverpool Women's NHS Foundation Trust, Liverpool, UK ³⁹Oxford NHS Regional Molecular Genetics Laboratory, Oxford University Hospitals NHS Trust, Oxford, UK ⁴⁰Division of Genetics, King's College London, Guy's Hospital, London, UK ⁴¹Craniofacial Unit, Department of Plastic and Reconstructive Surgery, Oxford University Hospitals NHS Trust, Oxford, UK ⁴²Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, St Louis, Missouri, USA ⁴³Office of the Regius Professor of Medicine, University of Oxford, Oxford, UK

Acknowledgements

Funded by a Wellcome Trust Core Award (090532/Z/09/Z) and Medical Research Council Hub grant (G0900747 91070) to PD, the National Institute for Health Research (NIHR) Biomedical Research Centre Oxford, the Department of Health's NIHR Biomedical Research Centres funding scheme, and Illumina Inc. Additional support is acknowledged from the BBSRC (BB/I02593X/1) to GL and GMV; Wellcome Trust grants 093329, 091182, and 102731 to AOMW, and 100308 to LF; the Newlife Foundation for Disabled Children (10-11/04) to AOMW; AtaxiaUK to AHN; the Haemochromatosis Society to KR; the European Research Council (FP7/2007-2013) Grant agreement no. 281824 to JCK and no. 305608 to OD, the Jeffrey Modell Foundation NYC and Baxter Healthcare to SYP and H. Chapel; Action de Recherche Concertée (ARC10/15-029, Communauté Française de Belgique) to OD; FNRS, FRSM and Inter-University Attraction Pole (IUAP, Belgium Federal Government) to OD; the NCCR Kidney.CH program (Swiss National Science Foundation) to OD; the Gebert R f Stiftung (Project GRS-038/12) to OD; the Swiss National Science Foundation 310030-146490 to OD; the Shriners Hospitals for Children (grant 15958) to MW; the Medical Research Council grants G9825289 and G1000467 to RVT, G1000801 to DH, and MC_UC_12010/3 to LF. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.

We would like to thank the patients and their families who consented to these studies and the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics for the generation of the sequencing data. Additionally, we are grateful to F. Harrington, C. Mignon, V. Sharma, I. Taylor and I. Westbury for assistance with molecular genetic analysis, and the staff of the OUH NHS Immunology Laboratory for DNA preparation.

URLs

Stampy read mapper, <http://www.well.ox.ac.uk/project-stampy>

Platypus variant caller, <https://github.com/andyrimmer/Platypus>

Picard, www.picard.sourceforge.net

Ensembl regulatory build, http://www.ensembl.org/info/docs/funcgen/regulatory_build.html

NHLBI Exome Variant Server, <http://evs.gs.washington.edu/EVS>

Copenhagen disease gene association list, <http://diseases.jensenlab.org/Search>

Eurexpress database, <http://discovery.lifemapsc.com/gene-expression-signals/high-throughput/ish-large-scale-dataset-eurexpress>

Universal Mutation Database for *BRCA2*: <http://www.umd.be/BRCA2>

References for main text

1. Need AC, et al. Clinical application of exome sequencing in undiagnosed genetic conditions. *J Med Genet.* 2012; 49:353–61. [PubMed: 22581936]
2. Bamshad MJ, et al. Exome sequencing as a tool for Mendelian disease gene discovery. *Nat Rev Genet.* 2011; 12:745–55. [PubMed: 21946919]
3. Yang Y, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. *N Engl J Med.* 2013; 369:1502–11. [PubMed: 24088041]
4. Gonzaga-Jauregui C, Lupski JR, Gibbs RA. Human genome sequencing in health and disease. *Annu Rev Med.* 2012; 63:35–61. [PubMed: 22248320]
5. Dixon-Salazar TJ, et al. Exome sequencing can improve diagnosis and alter patient management. *Sci Transl Med.* 2012; 4:138ra78.
6. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature.* 2012; 491:56–65. [PubMed: 23128226]
7. Tennessen JA, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. *Science.* 2012; 337:64–9. [PubMed: 22604720]
8. Beaulieu CL, et al. FORGE Canada Consortium: Outcomes of a 2-Year National Rare-Disease Gene-Discovery Project. *Am J Hum Genet.* 2014; 94:809–17. [PubMed: 24906018]
9. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. *N Engl J Med.* 2014; 370:2418–25. [PubMed: 24941179]
10. Saunders CJ, et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. *Sci Transl Med.* 2012; 4:154ra135.
11. Gilissen C, et al. Genome sequencing identifies major causes of severe intellectual disability. *Nature.* 2014; 511:344–7. [PubMed: 24896178]
12. Jacob HJ, et al. Genomics in clinical practice: lessons from the front lines. *Sci Transl Med.* 2013; 5:194cm5.
13. Cazier JB, et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. *Nat Commun.* 2014; 5:3756. [PubMed: 24777035]
14. Babbs C, et al. Homozygous mutations in a predicted endonuclease are a novel cause of congenital dyserythropoietic anemia type I. *Haematologica.* 2013; 98:1383–7. [PubMed: 23716552]
15. Martin HC, et al. Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. *Hum Mol Genet.* 2014
16. Sharma VP, et al. Mutations in TCF12, encoding a basic helix-loop-helix partner of TWIST1, are a frequent cause of coronal craniosynostosis. *Nat Genet.* 2013; 45:304–7. [PubMed: 23354436]
17. Cossins J, et al. Congenital myasthenic syndromes due to mutations in ALG2 and ALG14. *Brain.* 2013; 136:944–56. [PubMed: 23404334]
18. Lise S, et al. Recessive mutations in SPTBN2 implicate beta-III spectrin in both cognitive and motor development. *PLoS Genet.* 2012; 8:e1003074. [PubMed: 23236289]

19. Palles C, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat Genet.* 2012; 45:136–144. [PubMed: 23263490]
20. McCarthy DJ, et al. Choice of transcripts and software has a large effect on variant annotation. *Genome Med.* 2014; 6:26. [PubMed: 24944579]
21. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic acids research.* 2010; 38:e164. [PubMed: 20601685]
22. McLaren W, et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. *Bioinformatics.* 2010; 26:2069–70. [PubMed: 20562413]
23. Nelson MR, et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. *Science.* 2012; 337:100–4. [PubMed: 22604722]
24. Stenson PD, et al. The Human Gene Mutation Database: 2008 update. *Genome Med.* 2009; 1:13. [PubMed: 19348700]
25. Pagel P, et al. The MIPS mammalian protein-protein interaction database. *Bioinformatics.* 2005; 21:832–4. [PubMed: 15531608]
26. de Ligt J, et al. Diagnostic exome sequencing in persons with severe intellectual disability. *N Engl J Med.* 2012; 367:1921–9. [PubMed: 23033978]
27. Swaminathan G, Tsygankov AY. The Cbl family proteins: ring leaders in regulation of cell signaling. *J Cell Physiol.* 2006; 209:21–43. [PubMed: 16741904]
28. Denayer E, Legius E. What's new in the neuro-cardio-facial-cutaneous syndromes? *Eur J Pediatr.* 2007; 166:1091–8. [PubMed: 17611774]
29. Martinelli S, et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. *Am J Hum Genet.* 2010; 87:250–7. [PubMed: 20619386]
30. Niemeyer CM, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. *Nat Genet.* 2010; 42:794–800. [PubMed: 20694012]
31. Perez B, et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. *J Med Genet.* 2010; 47:686–91. [PubMed: 20543203]
32. Nava C, et al. Analysis of the chromosome X exome in patients with autism spectrum disorders identified novel candidate genes, including TMLHE. *Transl Psychiatry.* 2012; 2:e179. [PubMed: 23092983]
33. Isrie M, et al. HUWE1 mutation explains phenotypic severity in a case of familial idiopathic intellectual disability. *Eur J Med Genet.* 2013; 56:379–82. [PubMed: 23721686]
34. Froyen G, et al. Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental retardation. *Am J Hum Genet.* 2008; 82:432–43. [PubMed: 18252223]
35. McMullin MF. The classification and diagnosis of erythrocytosis. *Int J Lab Hematol.* 2008; 30:447–59. [PubMed: 18823397]
36. Jelkmann W. Regulation of erythropoietin production. *Journal of Physiology.* 2011; 589:1251–8. [PubMed: 21078592]
37. Bowl MR, et al. An interstitial deletion-insertion involving chromosomes 2p25.3 and Xq27.1, near SOX3, causes X-linked recessive hypoparathyroidism. *J. Clin. Invest.* 2005; 115:2822–31. [PubMed: 16167084]
38. Zajac JD, Danks JA. The development of the parathyroid gland: from fish to human. *Current Opinion in Nephrology and Hypertension.* 2008; 17:353–6. [PubMed: 18660669]
39. Green RC, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genetics in Medicine.* 2013; 15:565–74. [PubMed: 23788249]
40. MacArthur DG, et al. Guidelines for investigating causality of sequence variants in human disease. *Nature.* 2014; 508:469–76. [PubMed: 24759409]
41. Metcalfe K, et al. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. *J Natl Cancer Inst.* 2010; 102:1874–8. [PubMed: 21098759]
42. Zuk O, et al. Searching for missing heritability: designing rare variant association studies. *Proc Natl Acad Sci U S A.* 2014; 111:E455–64. [PubMed: 24443550]

43. Moutsianas L, et al. The Power of Gene-based Rare Variant Methods to Detect Disease-associated Variation and Test Hypotheses about Complex Disease. *PLoS Genet.* in press.
44. Kapplinger JD, et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. *J Am Coll Cardiol.* 2011; 57:2317–27. [PubMed: 21636032]
45. Castera L, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. *Eur J Hum Genet.* 2014; 22:1305–13. [PubMed: 24549055]
46. Chong HK, et al. The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay. *PLoS One.* 2014; 9:e97408. [PubMed: 24830819]
47. Borg A, et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. *Hum Mutat.* 2010; 31:E1200–40. [PubMed: 20104584]
48. Rebbeck TR, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol.* 2004; 22:1055–62. [PubMed: 14981104]
49. Hakansson S, et al. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. *Am J Hum Genet.* 1997; 60:1068–78. [PubMed: 9150154]
50. Landrum MJ, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res.* 2014; 42:D980–5. [PubMed: 24234437]
51. Caputo S, et al. Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. *Nucleic Acids Res.* 2012; 40:D992–1002. [PubMed: 22144684]
52. Brohet RM, et al. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. *J Med Genet.* 2014; 51:98–107. [PubMed: 24285858]
53. Moss AJ, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. *Circulation.* 2007; 115:2481–9. [PubMed: 17470695]
54. Choi G, et al. Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes. *Circulation.* 2004; 110:2119–24. [PubMed: 15466642]
55. Kapplinger JD, et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. *Heart Rhythm.* 2009; 6:1297–303. [PubMed: 19716085]
56. Crotti L, et al. Long QT syndrome-associated mutations in intrauterine fetal death. *JAMA.* 2013; 309:1473–82. [PubMed: 23571586]
57. Li Y, et al. Intracellular ATP binding is required to activate the slowly activating K⁺ channel I(Ks). *Proc Natl Acad Sci U S A.* 2013; 110:18922–7. [PubMed: 24190995]
58. Vukcevic M, et al. Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease. *Anesth Analg.* 2010; 111:185–90. [PubMed: 20142353]

Methods only references

59. Lamble S, et al. Improved workflows for high throughput library preparation using the transposome-based Nextera system. *BMC Biotechnol.* 2013; 13:104. [PubMed: 24256843]
60. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* 2009; 25:1754–60. [PubMed: 19451168]
61. Lunter G, Goodson M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. *Genome Res.* 2011; 21:936–9. [PubMed: 20980556]
62. Rimmer A, et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. *Nat Genet.* 2014; 46:912–8. [PubMed: 25017105]
63. Pagnamenta AT, et al. Exome sequencing can detect pathogenic mosaic mutations present at low allele frequencies. *J Hum Genet.* 2012; 57:70–2. [PubMed: 22129557]

64. Ruark E, et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. *Nature*. 2013; 493:406–10. [PubMed: 23242139]
65. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform*. 2012
66. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*. 2010; 38:e164. [PubMed: 20601685]
67. Yau C. OncoSNP-SEQ: a statistical approach for the identification of somatic copy number alterations from next-generation sequencing of cancer genomes. *Bioinformatics*. 2013; 29:2482–4. [PubMed: 23926227]
68. Plagnol V, et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. *Bioinformatics*. 2012; 28:2747–54. [PubMed: 22942019]
69. McQuillan R, et al. Runs of homozygosity in European populations. *Am J Hum Genet*. 2008; 83:359–72. [PubMed: 18760389]
70. Colella S, et al. QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data. *Nucleic Acids Res*. 2007; 35:2013–25. [PubMed: 17341461]
71. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin--rapid analysis of dense genetic maps using sparse gene flow trees. *Nat Genet*. 2002; 30:97–101. [PubMed: 11731797]
72. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*. 2010; 26:841–2. [PubMed: 20110278]
73. Diez-Roux G, et al. A high-resolution anatomical atlas of the transcriptome in the mouse embryo. *PLoS Biol*. 2011; 9:e1000582. [PubMed: 21267068]





Figure 1. Overview of projects and results

For each disorder, the number of independent cases (bars) studied is shown alongside information about the nature of the disorder: familial disorders (category 1, light green triangles), severe single-generation disorders suspected to be caused by *de novo* or recessive mutations (category 2, dark green), unrelated sporadic disorders (category 3, light blue) and extreme cases of common complex diseases (category 4, dark blue). The proportion of cases with each outcome class A-E is also shown (see Online Methods): pathogenic variant in novel gene for disorder (A, red circles), pathogenic variant in gene for related disorder (B, brown), pathogenic variant in known gene for disorder (C, pink), candidate pathogenic variant with validation studies underway (D, orange) and no single candidate variant, or negative results for validation of top candidate/s (blue). Size of points proportional to outcome fraction. Disorders are ranked by fraction of cases with confirmed pathogenic variants (class A to C).






Figure 3. Identification of *de novo* *HUWE1* mutation associated with severe craniosynostosis (a) Upper panel, the proband (CRS_4659; female, aged 6 months) presented with an abnormal skull shape. Lower panel, three-dimensional CT scan aged 5 months shows multisuture synostosis with multiple craniolacunae. (b) Family pedigree showing dideoxy sequence chromatograms with *de novo* G>A mutation of the X-linked *HUWE1* gene in the proband (red arrow). Schematic X chromosomes are annotated from top to bottom with the *HUWE1* alleles, haplotype of AA/CC polymorphisms located 1.15 kb away from mutation and used to deduce paternal origin, and androgen receptor (AR) trinucleotide repeat allele size (allele sizes in CRS_4654 and CRS_5215 are in brackets to emphasize that phase is unknown relative to other parts of the two X chromosomes). Note that the *HUWE1* mutation abolishes a *HpaII* restriction site. (c) Analysis of X-inactivation in whole blood samples at AR locus. For each individual, AR alleles are indicated by arrows in the upper panel, while the lower panel shows proportions of methylated alleles and percentage representation of the more highly inactivated X chromosome. (d) Exclusive expression of cDNA from the *HUWE1* mutant allele in both fibroblast (Fib) and Epstein Barr virus (EBV)-transformed lymphoblastoid cells from the proband. Arrows highlight absence of expression of the normal allele in either cell type. Product sizes (bp) from different alleles are shown on the right. WT: wild-type, Mut: mutant. (e) X chromosome ideogram showing eight *de novo* mutations identified. Where known, the parental allele on which the variant arose is indicated.




Figure 4. Candidate pathogenic noncoding variants

(a) Multi-species alignment of a region of the 5' UTR of *EPO* in which a variant was identified at a conserved position (red text) in two families with erythrocytosis. (b) Erythrocytosis pedigrees studied, showing affected individuals (shaded grey), those sequenced (red borders), and genotypes of all individuals for whom we had DNA. We had no information about the father of PAR09 (dotted box). (c) Summary of read mapping in an individual with hypoparathyroidism showing evidence for an interstitial insertion-deletion event in which a ~ 50 kb region of chromosome 2p25.3 (top panel) has been duplicated and inserted into chromosome X, resulting in a 1.4 kb deletion 81.5 kb downstream of *SOX3* (bottom panel). Yellow reads: mate maps to chrX; red reads: mate maps to chr2; grey reads: read and mate map to the same chromosome; white reads: read has mapping quality 0. (d) Pedigree showing segregation of the complex variant within the affected pedigree, with PCR validation below. M: mutation; N: normal. Primers 2SPF and XSPR flank the distal breakpoint of the deletion-insertion and are shown in Supplementary Figure 8. Primers XSPF and XSPR detect the normal allele. The mutation was not seen in 150 alleles from 100 unrelated normocalcemic individuals (50 males and 50 females, including N1 and N2, who are shown).

Table 1
Summary of conditions for which pathogenic genes were identified (class A, B or C)

Disease	Project category	Result class	Gene ^a	Coding consequence	Inheritance (Zygosity) ^b	Variant
Acquired essential thrombocytosis	1.1	C	<i>THPO</i>	splicing	D (het)	NM_001177598: c.13+1G>C
Asplenia	2.2	C	<i>RPSA</i> ^C	splicing	D (het)	NM_002295.4: c.-34+5G>C
Cerebellar ataxia	1.2	B	<i>SPTBN2</i>	nonsense	AR (hom)	NM_006946: c.1881G>A; p.C627*
Common variable immunodeficiency disorder	3	C	<i>d</i>	missense	<i>d</i>	<i>d</i>
Congenital dyserythropoietic anaemia, type 1	1.2	A	<i>C15ORF41</i>	missense	AR (hom)	NM_001130010: c.533T>A; p.L178Q
Congenital myasthenic syndrome	3	B	<i>ALG2</i>	missense	AR (hom)	NM_033087: c.203T>G; p.V68G
Craniosynostosis	2.1	A	<i>ZIC1</i>	nonsense	DN (het)	NM_003412.3: c.1163C>A; p.S388*
	2.1	B	<i>HUWE1</i>	missense	DN (het)	NM_031407.6: c.329G>A; p.R110Q
Erythrocytosis	1.1	A	<i>EPO</i>	noncoding	D (het)	NM_000799.2: c.-136G>A
	1.1	A	<i>EPO</i>	noncoding	D (het)	NM_000799.2: c.-136G>A
	3	C	<i>BPGM</i>	missense	D (het)	NM_001724: c.269G>A; p.R90H
Familial hypoparathyroidism	1.3	C	<i>SOX3</i>	noncoding	XL (hemi)	deletion of chrX:139,502,946-139,504,327, 1.5kb downstream of SOX3
	1.1	C	<i>CASR</i>	missense	D (het)	NM_000388: c.2299G>C; p.E767Q
Familial juvenile hyperuricaemic nephropathy	1.4	C	<i>UMOD</i>	missense	D (het)	NM_001008389: c.410G>A; p.C137Y
Familial tubulo-interstitial nephropathy	1.1	C	<i>UMOD</i>	missense (inframe insertion/deletion)	D (het)	NM_001008389: c.279_289del; p.93_97del; NM_001008389: c.278_279insCCGCCTCC; p.V9 3fs
Hypertrophic cardiomyopathy (sarcomere gene-negative)	1.1	C	<i>MYBPC3</i>	nonsense	<i>e</i>	NM_000256: c.1303C>T; p.Q435*
Inflammatory bowel syndrome/colitis	4	A	<i>d</i>	missense	<i>d</i>	<i>d</i>
Interstitial nephritis	1.4	C	<i>MUC1</i> ^C	-	D (het)	<i>d</i>
Long QT syndrome	1.1	C	<i>KCNQ1</i>	missense	D (het)	NM_000218: c.1195_1196insC; p.A399fs
Mental retardation	2.1	C	<i>GRIA3</i>	missense	XL (hemi)	<i>a</i>
Ohtahara syndrome and other early-onset epilepsies	2.1	A	<i>PIGQ</i>	splicing	SR (hom)	NM_004204: c.690-2A>G
	2.1	B	<i>KCNT1</i>	missense	UPID (hom)	NM_020822: c. 2896G>A; p.A966T
	2.1	C	<i>KCNQ2</i>	missense	DN (het)	NM_004518: c.827C>T; p.T276I
	2.1	C	<i>SCN2A</i>	missense	DN (het)	NM_001040143: c.5558A>G; p.H1853R
Multiple adenoma	1.1	A	<i>POLD1</i>	missense	D (het)	NM_002691: c.1433G>A; p.S478N
	1.1	A	<i>POLD1</i>	missense	D (het)	NM_002691: c.1433G>A; p.S478N
	4	A	<i>POLE</i>	missense	D (het)	NM_006231: c.1270C>G; p.L424V
	4	C	<i>MSH6</i>	missense and nonsense	CR (het; het)	NM_000179: c.2315G>A; p.R772Q
	4	C	<i>BMPRI1A</i>	frameshift	AR (hom)	NM_004329.2: c.142_143insT; p.Thr49Asnfs*2 2
	4	C	<i>APC</i>	splicing	D (het)	NM_001127511: c.251-2A>G
Saethre-Chotzen syndrome (TWIST1 negative)	3	A	<i>TCF12</i>	nonsense	DN (het)	NM_207037.1: c.1283T>G; p.L428*
	3	A	<i>TCF12</i>	splicing	DN (het)	NM_207037.1: c.1035+3G>C
	2.1	A	<i>CDC45</i>	synonymous (splicing) and missense	CR (het; het)	NM_001178010.2: c.318C>T; p.V106=; NM_001178010.2: c.773A>G; p.D258G

^a Each line represents a separate case or family, so if the same gene is reported on two lines, this signifies that the gene is thought to be pathogenic in both cases. Some genes have two mutations in the same affected individual, likely representing compound heterozygous inheritance, which is indicated in the Inheritance column.

^b_D(het): dominant - affected individual/s heterozygous; AR (hom): autosomal recessive – affected individual/s homozygous; DN (het) :*de novo* – affected individual/s heterozygous; XL (hemi): X-linked recessive – affected male/s hemizygous, affected female/s homozygous; UPD (hom): uniparental isodisomy–affected individual homozygous; CR (het; het): compound recessive – affected individual /s heterozygous for two different variants in the same gene

^c Causal variant discovered independently of WGS500.

^d Details will be reported in an independent publication.

^e Form of inheritance not clear. See Supplementary Table 8.

Table 2
Incidental findings with potentially actionable consequences

Incidental finding condition	Gene	AA change	UK10K	EVS_EA	Comments
I. Reportable Incidental Findings					
Arrhythmogenic right ventricular cardiomyopathy (ARVC)	<i>DSG2</i>	NM_001943: c.2397T>G:p.Y799*	absent	absent	Stop gain mutation, not previously reported, but mutation class considered pathogenic ⁴⁴
	<i>DSG2</i>	NM_001943: c.2554G>T:p.E852*	absent	absent	As above
Breast & ovarian cancer	<i>BRCA2</i>	NM_000059: c.7558C>T:p.R2520*	absent	0.0001	Stop gain mutation; 5 independent R2520* in affected patients ⁴⁵⁻⁴⁹ , 4 reports of variant being pathogenic in ClinVar ⁵⁰ (submitted by independent clinical labs) and 7 records rated as causal in UMD-BRCA2 database ⁵¹ . Mutations of this class described in Brohet, et al. ⁵² .
Long QT syndrome	<i>KCNQ1</i>	NM_000218: c.877C>T:p.R293C	absent	absent	2 independent reports in literature: i) 4 / 2500 independent cases from FAMILION cohort referred for LQT genetic testing ⁵³ and ii) 1 case /388 consecutive unrelated patients with swimming triggered arrhythmia syndromes ⁵⁴ , as compound heterozygote with G269D. Location of mutation in pore suggestive of pathogenicity.
II. Incidental Findings of Uncertain Significance					
Long QT syndrome	<i>KCNQ1</i>	NM_000218: c.1189C>T:p.R397W	absent	0.0006	3 independent reports in literature, including 3/2500 independent cases referred for long QT testing ⁵⁵ , 5/600 cases in LQT registry ⁵³ and 1/91 independent cases of intrauterine foetal death ⁵⁶ . Functional data from heterologous expression of mutation i) in HEK293 cells which shows markedly reduced current on whole cell patch clamp compared with WT ⁵⁶ and ii) in inside-out membrane patches from <i>Xenopus</i> oocytes which showed markedly reduced ATP binding ⁵⁷ . Taken together, this suggests that the mutation should not be disregarded clinically as it may be weakly pathogenic, albeit with low absolute risk
Malignant hyperthermia	<i>RYR1</i>	NM_000540: c.5036G>A:p.R1679H	0.0006	0.0014	Variant observed in single subject with complication, and positive functional testing ⁵⁸ but no independent replication.

Variants deemed to be reportable and clinically actionable are listed Section I of the table. Those for which the evidence was not considered sufficient to be clinically actionable are reported or are uncertain are listed in Section II.

AA: amino acid; VUS: variant of unknown significance; UK10K: frequency in the UK10K twin cohort; EVS: Exome Variant Server; EVS_EA: frequency in European Americans in the EVS; HGMD: Human Gene Mutation Database; UMD: Universal Mutation Database (see URLs).